TLR5: Toll-like receptor 5
Pattern recognition receptor (PRR) located on the cell surface that participates in the activation of innate immunity and inflammatory response.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on TLR5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Entolimod | Phase 2 | BioLab 612 LLC | Other | AgonistToll-like receptor 5 agonist | 0 |
- Inborn error of immunity0.37
- Contact dermatitis0.29
- Drug allergy0.28
- Alzheimer disease0.28
- Alcohol drinking0.20
- Alopecia areata0.20
- Preeclampsia0.16
- Male reproductive organ cancer0.15
- Left bundle branch block0.14
- Hypotensive disorder0.14
- Coronary atherosclerosis0.13
- Neoplasm0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2176839, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O60602, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets